minocycline

Summary

Summary: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.

Top Publications

  1. ncbi Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia
    T Tikka
    A. I. Virtanen Institute for Molecular Sciences, University of Kuopio, FIN-70211 Kuopio, Finland
    J Neurosci 21:2580-8. 2001
  2. ncbi Minocycline and neurodegenerative diseases
    Hye Sun Kim
    Department of Pharmacology, Seoul National University, College of Medicine, Seoul, Republic of Korea
    Behav Brain Res 196:168-79. 2009
  3. ncbi TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice
    Chaohui Zhao
    Department of Pharmacology, Rush University Medical Center, 1735 W Harrison St, Cohn Research Building, Suite 406, Chicago, IL 60612, USA
    Neurobiol Dis 26:36-46. 2007
  4. ncbi Minocycline treatment in acute stroke: an open-label, evaluator-blinded study
    Y Lampl
    Department of Neurology, Edith Wolfson Medical Center, Holon 58100, Israel
    Neurology 69:1404-10. 2007
  5. ncbi Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis
    Jasna Kriz
    Centre for Research in Neurosciences, McGill University, Research Institute of the McGill University Health Centre, , , H3G 1A4, Canada
    Neurobiol Dis 10:268-78. 2002
  6. ncbi Minocycline delays disease onset and mortality in a transgenic model of ALS
    Ludo Van Den Bosch
    Laboratory for Neurobiology, Campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium
    Neuroreport 13:1067-70. 2002
  7. ncbi Antioxidant potential of Minocycline in Japanese Encephalitis Virus infection in murine neuroblastoma cells: correlation with membrane fluidity and cell death
    Manoj Kumar Mishra
    National Brain Research Centre, Manesar, Haryana 122050, India
    Neurochem Int 54:464-70. 2009
  8. ncbi Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease
    D C Wu
    Department of Neurology, Columbia University, New York, New York 10032, USA
    J Neurosci 22:1763-71. 2002
  9. ncbi The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study
    R K Zabad
    Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    Mult Scler 13:517-26. 2007
  10. ncbi Activation of glia and microglial p38 MAPK in medullary dorsal horn contributes to tactile hypersensitivity following trigeminal sensory nerve injury
    Zheng Gen Piao
    Department of Physiology, College of Dentistry and Dental Research Institute, Seoul National University, Seoul 110 749, Republic of Korea
    Pain 121:219-31. 2006

Research Grants

Detail Information

Publications238 found, 100 shown here

  1. ncbi Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia
    T Tikka
    A. I. Virtanen Institute for Molecular Sciences, University of Kuopio, FIN-70211 Kuopio, Finland
    J Neurosci 21:2580-8. 2001
    b>Minocycline, a semisynthetic tetracycline derivative, protects brain against global and focal ischemia in rodents. We examined whether minocycline reduces excitotoxicity in primary neuronal cultures. Minocycline (0...
  2. ncbi Minocycline and neurodegenerative diseases
    Hye Sun Kim
    Department of Pharmacology, Seoul National University, College of Medicine, Seoul, Republic of Korea
    Behav Brain Res 196:168-79. 2009
    b>Minocycline is a semi-synthetic, second-generation tetracycline analog which is effectively crossing the blood-brain barrier, effective against gram-positive and -negative infections...
  3. ncbi TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice
    Chaohui Zhao
    Department of Pharmacology, Rush University Medical Center, 1735 W Harrison St, Cohn Research Building, Suite 406, Chicago, IL 60612, USA
    Neurobiol Dis 26:36-46. 2007
    ..using the FITC-LA technique in wild-type (WT), tumor necrosis factor alpha (TNF-alpha) knockout (KO), and minocycline (an inhibitor of microglia activation) treated mice 72 h following treatment with 1-methyl-4-phenyl-1,2,3,6-..
  4. ncbi Minocycline treatment in acute stroke: an open-label, evaluator-blinded study
    Y Lampl
    Department of Neurology, Edith Wolfson Medical Center, Holon 58100, Israel
    Neurology 69:1404-10. 2007
    Ischemic animal model studies have shown a neuroprotective effect of minocycline.
  5. ncbi Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis
    Jasna Kriz
    Centre for Research in Neurosciences, McGill University, Research Institute of the McGill University Health Centre, , , H3G 1A4, Canada
    Neurobiol Dis 10:268-78. 2002
    ..inflammation and caspase activation may contribute to neurodegeneration in ALS, we tested the effects of minocycline, a second-generation tetracycline with anti-inflammatory properties, in mice expressing a mutant superoxide ..
  6. ncbi Minocycline delays disease onset and mortality in a transgenic model of ALS
    Ludo Van Den Bosch
    Laboratory for Neurobiology, Campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium
    Neuroreport 13:1067-70. 2002
    ..As minocycline has been shown to inhibit microglial activation, the therapeutic efficacy of this tetracycline derivative in ..
  7. ncbi Antioxidant potential of Minocycline in Japanese Encephalitis Virus infection in murine neuroblastoma cells: correlation with membrane fluidity and cell death
    Manoj Kumar Mishra
    National Brain Research Centre, Manesar, Haryana 122050, India
    Neurochem Int 54:464-70. 2009
    b>Minocycline is neuroprotective in animal models of a number of acute CNS injuries, neurodegenerative diseases and CNS infection...
  8. ncbi Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease
    D C Wu
    Department of Neurology, Columbia University, New York, New York 10032, USA
    J Neurosci 22:1763-71. 2002
    ..Consistent with a role of glial cells in PD neurodegeneration, here we show that minocycline, an approved tetracycline derivative that inhibits microglial activation independently of its antimicrobial ..
  9. ncbi The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study
    R K Zabad
    Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    Mult Scler 13:517-26. 2007
    b>Minocycline has immunomodulatory and neuroprotective activities in vitro and in an animal model of multiple sclerosis (MS)...
  10. ncbi Activation of glia and microglial p38 MAPK in medullary dorsal horn contributes to tactile hypersensitivity following trigeminal sensory nerve injury
    Zheng Gen Piao
    Department of Physiology, College of Dentistry and Dental Research Institute, Seoul National University, Seoul 110 749, Republic of Korea
    Pain 121:219-31. 2006
    ..b>Minocycline, an inhibitor of microglial activation, reduced microglial activation, inhibited p38 mitogen-activated protein ..
  11. ncbi Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum
    Y He
    Department of Neurology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Brain Res 909:187-93. 2001
    ..We further investigated the effect of minocycline on the inhibition of microglial activation and subsequent protection of nigral cells...
  12. ncbi Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model
    T V Bilousova
    Biomedical Sciences, University of California, 900 University Ave, Riverside, CA 92521 0121, USA
    J Med Genet 46:94-102. 2009
    ..b>Minocycline is a tetracycline analogue that has been used in clinical trials for stroke, multiple sclerosis and several ..
  13. ncbi Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases
    Christopher Power
    Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    Ann Neurol 53:731-42. 2003
    ..showed that thrombin, released during ICH, induced MMP-12 expression in monocytoid cells, which was reduced by minocycline application. Similarly, in vivo minocycline treatment significantly reduced MMP-12 levels in brain...
  14. ncbi RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae
    David Keeney
    Department of Infectious Disease, Wyeth Research, 401 North Middletown Road, Pearl River, NY 10965, USA
    Microb Drug Resist 13:1-6. 2007
    ..These results suggest that decreased susceptibility to tigecycline in E. cloacae is the result of RamA-mediated overexpression of the AcrAB efflux pump...
  15. ncbi Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity
    Millicent Stone
    Division of Rheumatology, Department of Medicine, Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada
    J Rheumatol 30:2112-22. 2003
    ..17, 95% CI -0.29, 0.64. In addition, subgroup analysis excluding trials with doxycycline showed that minocycline alone had a greater effect on reduction of disease activity: for TJC, SMD = -0.69, 95% CI -0.89, -0...
  16. ncbi A novel action of minocycline: inhibition of human immunodeficiency virus type 1 infection in microglia
    Qiusheng Si
    Department of Pathology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    J Neurovirol 10:284-92. 2004
    ..In this report, the authors demonstrate that minocycline (MC), a second-generation tetracycline with proven safety and penetration to the central nervous system, ..
  17. ncbi Minocycline inhibits apoptotic cell death via attenuation of TNF-alpha expression following iNOS/NO induction by lipopolysaccharide in neuron/glia co-cultures
    Sang M Lee
    Biomedical Research Center, Korea Institute of Science and Technology, Seoul, Korea
    J Neurochem 91:568-78. 2004
    We attempted to ascertain the neuroprotective effects and mechanisms of minocycline in inflammatory-mediated neurotoxicity using primary neuron/glia co-cultures treated with lipopolysaccharide (LPS)...
  18. ncbi Neuroprotective and anti-human immunodeficiency virus activity of minocycline
    M Christine Zink
    Department of Comparative Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    JAMA 293:2003-11. 2005
    ..Current antiretroviral drugs are expensive, have significant adverse effects including neurotoxicity, and few cross the blood-brain barrier...
  19. ncbi Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice
    Hiroyuki Mizoguchi
    Laboratory of Neuropsychopharmacology, Division of Life Sciences, Graduate School of Natural Science and Technology, Kanazawa University, Kanazawa 920 1192, Japan
    Psychopharmacology (Berl) 196:233-41. 2008
    ..Recent studies indicate that minocycline, a second-generation tetracycline, has potent neuroprotective effects in various animal models of neurological ..
  20. ncbi MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli
    David Keeney
    Wyeth Research, Pearl River, NY, USA
    J Antimicrob Chemother 61:46-53. 2008
    ..The purpose of this study was to characterize decreased susceptibility to tigecycline in clinical isolates of Escherichia coli obtained during Phase 3 clinical trials...
  21. ncbi Open-label add-on treatment trial of minocycline in fragile X syndrome
    Carlo Paribello
    Surrey Place Centre, Toronto, Ontario, Canada
    BMC Neurol 10:91. 2010
    ..b>Minocycline inhibits MMP-9 activity, and alleviates behavioural and synapse abnormalities in fmr1 knockout mice, an ..
  22. ncbi Proton magnetic resonance spectroscopy reveals neuroprotection by oral minocycline in a nonhuman primate model of accelerated NeuroAIDS
    Eva Maria Ratai
    AA Martinos Center for Biomedical Imaging and Neuroradiology Division, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America
    PLoS ONE 5:e10523. 2010
    ..and alleviate neurocognitive deficits associated with HIV, we used an accelerated simian immunodeficiency virus (SIV) macaque model of NeuroAIDS to test whether minocycline is neuroprotective against lentiviral-induced neuronal injury.
  23. ncbi ramR mutations in clinical isolates of Klebsiella pneumoniae with reduced susceptibility to tigecycline
    M Hentschke
    Institute of Medical Microbiology, Virology and Hygiene, University Medical Centre Hamburg Eppendorf, Martinistrasse, Hamburg, Germany
    Antimicrob Agents Chemother 54:2720-3. 2010
    ..Thus, this study reveals a molecular mechanism for tigecycline resistance in Klebsiella pneumoniae...
  24. ncbi Minocycline treatment reduces white matter damage after excitotoxic striatal injury
    Joanilson S Guimarães
    Edmond and Lily Safra International Institute of Neuroscience of Natal, Natal RN, Brazil
    Brain Res 1329:182-93. 2010
    We investigated the protective effects of minocycline following white matter damage (WMD) in the rat striatum...
  25. ncbi Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells
    Gregory L Szeto
    Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Infect Dis 201:1132-40. 2010
    ..Other options may be useful for long-term therapy. The immunomodulatory antibiotic minocycline could be an effective, low-cost adjunctive treatment to HAART...
  26. ncbi Minocycline reduces the injury-induced expression of prodynorphin and pronociceptin in the dorsal root ganglion in a rat model of neuropathic pain
    J Mika
    Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
    Neuroscience 165:1420-8. 2010
    ..Interestingly, preemptive and repeated i.p. injection of minocycline reversed the activation of microglia/macrophages in the spinal cord and the trafficking of peripheral immune ..
  27. ncbi Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline
    L P Robertson
    Department of Rheumatology, Royal Cornwall Hospital, Truro, UK
    Ann Rheum Dis 62:267-9. 2003
    To evaluate the effect of minocycline as treatment for cutaneous calcinosis in limited cutaneous systemic sclerosis (lcSSc).
  28. ncbi Minocycline neuroprotects, reduces microglial activation, inhibits caspase 3 induction, and viral replication following Japanese encephalitis
    Manoj Kumar Mishra
    National Brain Research Centre, Manesar, Haryana, India
    J Neurochem 105:1582-95. 2008
    b>Minocycline is broadly protective in neurological disease models featuring inflammation and cell death and is being evaluated in clinical trials...
  29. ncbi Real-time PCR and statistical analyses of acrAB and ramA expression in clinical isolates of Klebsiella pneumoniae
    Alexey Ruzin
    Department of Infectious Disease, Wyeth Research, Pearl River, New York 10965, USA
    Antimicrob Agents Chemother 52:3430-2. 2008
    ..At MICs of 4 and 8 microg/ml, the expression of ramA was statistically significantly different from MICs of 2 microg/ml or less, supporting the tigecycline susceptibility breakpoint of <or=2 microg/ml for K. pneumoniae...
  30. ncbi Lack of neuroprotective effects of simvastatin and minocycline in a model of cervical spinal cord injury
    Jae H T Lee
    International Collaboration on Repair Discoveries, University of British Columbia, Vancouver, BC, Canada
    Exp Neurol 225:219-30. 2010
    b>Minocycline, a commonly prescribed tetracycline antibiotic, has shown promise as a potential therapeutic agent in animal models of numerous neurologic disorders such as amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's ..
  31. ncbi Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations
    Conrad C Alano
    Department of Neurology, University of California-San Francisco and Veterans Affairs Medical Center, 4150 Clement Street, San Francisco, CA 94121, USA
    Proc Natl Acad Sci U S A 103:9685-90. 2006
    ..Here we report that PARP-1 enzymatic activity is directly inhibited by minocycline and other tetracycline derivatives that have previously been shown to have neuroprotective and anti-..
  32. ncbi Activated microglia contribute to the maintenance of chronic pain after spinal cord injury
    Bryan C Hains
    Department of Neurology, Center for Neuroscience and Regeneration Research, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    J Neurosci 26:4308-17. 2006
    ..were decreased to both mechanical and thermal stimuli, intrathecal infusions of the microglial inhibitor minocycline were initiated...
  33. ncbi The age-related attenuation in long-term potentiation is associated with microglial activation
    Rebecca Griffin
    Trinity College Institute for Neuroscience and Physiology Department, Trinity College, Dublin, Ireland
    J Neurochem 99:1263-72. 2006
    ..the attenuation of long-term potentiation (LTP) was demonstrated using an inhibitor of microglial activation, minocycline; partial restoration of LTP in 15-month-old rats was observed following administration of minocycline...
  34. ncbi Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice
    Shan Zhu
    Neuroapoptosis Laboratory, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 417:74-8. 2002
    b>Minocycline mediates neuroprotection in experimental models of neurodegeneration. It inhibits the activity of caspase-1, caspase-3, inducible form of nitric oxide synthetase (iNOS) and p38 mitogen-activated protein kinase (MAPK)...
  35. ncbi Minocycline-mediated inhibition of microglia activation impairs oligodendrocyte progenitor cell responses and remyelination in a non-immune model of demyelination
    Wen-Wu Li
    Cambridge Centre for Brain Repair and Neuroregeneration Laboratory, Department of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge CB3 0ES, UK
    J Neuroimmunol 158:58-66. 2005
    b>Minocycline, a tetracycline derivative, disrupts inflammatory processes within the CNS and reduces demyelination in experimental autoimmune encephalomyelitis...
  36. ncbi Does minocycline have antidepressant effect?
    Chi Un Pae
    Department of Psychiatry, Kangnam St Mary s Hospital, The Catholic University of Korea College of Medicine, 505 Banpo Dong, Seocho Gu, Seoul 137 701, South Korea
    Biomed Pharmacother 62:308-11. 2008
    ..In this regard, we propose that the second-generation tetracycline "minocycline" may hold a potential as a new treatment for major depression...
  37. ncbi Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures
    Agustini Utari
    M I N D Institute, University of California at Davis Medical Center, USA
    Am J Intellect Dev Disabil 115:433-43. 2010
    b>Minocycline can rescue the dendritic spine and synaptic structural abnormalities in the fragile X knock-out mouse...
  38. ncbi Understanding the molecular mechanism of blood-brain barrier damage in an experimental model of Japanese encephalitis: correlation with minocycline administration as a therapeutic agent
    Manoj Kumar Mishra
    National Brain Research Centre, Manesar, Haryana 122050, India
    Neurochem Int 55:717-23. 2009
    ..b>Minocycline, a semisynthetic tetracycline, has been found to be broadly protective in neurological disease models featuring ..
  39. ncbi Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease
    Wendy Noble
    MRC Centre for Neurodegeneration Research, King s College London, Institute of Psychiatry, Department of Neuroscience, PO37, De Crespigny Park, London, SE5 8AF, UK
    FASEB J 23:739-50. 2009
    ..b>Minocycline, a tetracycline derivative, has potent antiinflammatory, antiapoptotic, and neuroprotective effects in several ..
  40. ncbi Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease
    Y Du
    Departmens of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Proc Natl Acad Sci U S A 98:14669-74. 2001
    ..We now report that minocycline, a semisynthetic tetracycline, recently shown to have neuroprotective effects in animal models of stroke/..
  41. ncbi Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine
    J R O'Dell
    University of Nebraska Medical Center, Omaha 68198 3025, USA
    Arthritis Rheum 44:2235-41. 2001
    To compare the efficacy of minocycline with that of a conventional disease-modifying antirheumatic drug (DMARD), hydroxychloroquine, in patients with early seropositive rheumatoid arthritis (RA).
  42. ncbi Protective effects of minocycline on 3,4-methylenedioxymethamphetamine-induced neurotoxicity in serotonergic and dopaminergic neurons of mouse brain
    Lin Zhang
    Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba 260-8670, Japan
    Eur J Pharmacol 544:1-9. 2006
    ..In this study, we investigated the effects of minocycline, a second-generation tetracycline derivative, on MDMA-induced neurotoxicity in the 5-HT and dopaminergic ..
  43. ncbi Drug rash, eosinophilia, and systemic symptoms syndrome: Two pediatric cases demonstrating the range of severity in presentation--A case of vancomycin-induced drug hypersensitivity mimicking toxic shock syndrome and a milder case induced by minocycline
    Amy E Vinson
    Department of Pediatrics, Rhode Island Hospital, Hasbro Children s Hospital, Providence, RI, USA
    Pediatr Crit Care Med 11:e38-43. 2010
    ....
  44. ncbi Minocycline attenuates experimental autoimmune encephalomyelitis in rats by reducing T cell infiltration into the spinal cord
    Maria Nikodemova
    Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53705, USA
    J Neuroimmunol 219:33-7. 2010
    We investigated the anti-inflammatory effects of minocycline in EAE, an animal model of MS. Minocycline, administered for two weeks after the clinical onset, significantly decreased the cumulative and mean clinical scores of EAE...
  45. ncbi Minocycline protects dopaminergic neurons against long-term rotenone toxicity
    Khaled Radad
    Department of Pathology, Faculty of Veterinary Medicine, Assiut University, Assiut, Egypt
    Can J Neurol Sci 37:81-5. 2010
    ..In Parkinson's disease, most of current therapies only provide symptomatic treatment and so far there is no drug which directly affects the disease process...
  46. ncbi Medication-associated depersonalization symptoms: report of transient depersonalization symptoms induced by minocycline
    Philip R Cohen
    University of Houston Health Center, Department of Dermatology, University of Texas Houston Medical School, Houston, TX, USA
    South Med J 97:70-3. 2004
    ..A woman developed depersonalization symptoms after initiation of minocycline therapy. Her symptoms ceased after treatment was stopped and recurred when she restarted the drug...
  47. ncbi Minocycline does not affect amyloid beta phagocytosis by human microglial cells
    Atoosa Familian
    Department of Psychiatry, VU University Medical Center, Amsterdam, The Netherlands
    Neurosci Lett 416:87-91. 2007
    ..b>Minocycline, a tetracycline derivative, is neuroprotective in various neurodegenerative models as well as human chronic ..
  48. ncbi Novel chitosan wound dressing loaded with minocycline for the treatment of severe burn wounds
    Shuichi Aoyagi
    Department of Drug Delivery Research, Hoshi University, 2 4 41 Ebara, Shinagawa ku, Tokyo 142 8501, Japan
    Int J Pharm 330:138-45. 2007
    Novel wound dressings composed of chitosan (CH) film and minocycline hydrochloride (MH) were prepared using commercial polyurethane film (Tegaderm) as a backing...
  49. ncbi Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
    Paul H Gordon
    Department of Neurology, Columbia University, New York, NY, USA
    Lancet Neurol 6:1045-53. 2007
    b>Minocycline has anti-apoptotic and anti-inflammatory effects in vitro, and extends survival in mouse models of some neurological conditions...
  50. ncbi Minocycline blocks bilirubin neurotoxicity and prevents hyperbilirubinemia-induced cerebellar hypoplasia in the Gunn rat
    Suizhen Lin
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Eur J Neurosci 22:21-7. 2005
    ..In this study, we have demonstrated that minocycline potently protects primary cultured rat cerebellar granule neurons against bilirubin neurotoxicity (IC50 ..
  51. ncbi Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke
    Noriyuki Matsukawa
    Department of Neurology, Medical College of Georgia, Augusta, GA 30912, USA
    BMC Neurosci 10:126. 2009
    b>Minocycline, a second-generation tetracycline with anti-inflammatory and anti-apoptotic properties, has been shown to promote therapeutic benefits in experimental stroke...
  52. ncbi Chronic treatment with minocycline preserves adult new neurons and reduces functional impairment after focal cerebral ischemia
    Zhengyan Liu
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94121, USA
    Stroke 38:146-52. 2007
    ..The aim of this current study is to determine the effect of minocycline on neurogenesis and functional recovery after cerebral focal ischemia.
  53. ncbi Impact of topical minocycline with third molar surgery on clinical recovery and health-related quality of life outcomes
    Mary F Stavropoulos
    Department of Oral and Maxillofacial Surgery, College of Dentistry, University of Florida, Gainesville, FL, USA
    J Oral Maxillofac Surg 64:1059-65. 2006
    ..quality of life (HRQOL) outcomes after third molar surgery in patients treated with or without topical minocycline at surgery...
  54. ncbi Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii
    Madhuri M Sopirala
    The Ohio State University Medical Center, University Hospital East, 1492 E Broad Street, Columbus, OH 43205, USA
    Antimicrob Agents Chemother 54:4678-83. 2010
    ..These findings indicate the utility of synergy testing to predict activity of specific antibiotic combinations against PDR A. baumannii...
  55. ncbi Effects of minocycline on cocaine sensitization and phosphorylation of GluR1 receptors in 5-lipoxygenase deficient mice
    Hu Chen
    The Psychiatric Institute, Department of Psychiatry, University of Illinois at Chicago, Chicago, IL 60612, USA
    Neuropharmacology 60:1058-63. 2011
    In wild-type (WT) mice, the antibiotic minocycline inhibits development of cocaine-induced locomotor sensitization. Some of the actions of minocycline may involve the 5-lipoxygenase (5-LOX) pathway...
  56. ncbi In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates
    Thean Yen Tan
    Laboratory Medicine Services, Changi General Hospital, 2 Simei Street 3, Singapore 529889
    J Antimicrob Chemother 60:421-3. 2007
    The study investigated the effect of colistin and minocycline when tested singly and in combination against Acinetobacter baumannii.
  57. ncbi Minocycline, a possible neuroprotective agent in Leber's hereditary optic neuropathy (LHON): studies of cybrid cells bearing 11,778 mutation
    Mohammad Fahad Haroon
    Institute of Medical Neurobiology, Otto von Guericke University of Magdeburg, Leipziger Strasse 44, D 39120 Magdeburg, Germany
    Neurobiol Dis 28:237-50. 2007
    ..Evaluating the efficacy of minocycline in LHON, the drug increased the survival of cybrid cells in contrast to the parental cells after thapsigargin-..
  58. ncbi Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model
    Karen E Bowker
    Bristol Centre for Antimicrobial Research and Evaluation, Department of Microbiology, Southmead Hospital, Westbury on Trym, Bristol BS105NB, United Kingdom
    Antimicrob Agents Chemother 52:4370-3. 2008
    Free drug serum concentrations of minocycline associated with the doses given to humans (100 mg every 12 hours for 24 hours) were simulated in an in vitro hollow-fiber pharmacokinetic model...
  59. ncbi Minocycline differentially modulates viral infection and persistence in an experimental model of Japanese encephalitis
    Kallol Dutta
    National Brain Research Centre, Manesar, Haryana, India
    J Neuroimmune Pharmacol 5:553-65. 2010
    ..Our previous studies have led to the identification of minocycline, a semi-synthetic antibiotic, as a protective drug in JE...
  60. ncbi Effect of minocycline on healing of replanted dog teeth after extended dry times
    E C Bryson
    Department of Endodontics, School of Dentistry, UNC at Chapel Hill, 27599, USA
    Dent Traumatol 19:90-5. 2003
    b>Minocycline is available as a locally administered tetracycline derivative antibiotic (Arestin, OraPharma, Inc...
  61. ncbi Minocycline prevents osmotic demyelination syndrome by inhibiting the activation of microglia
    Haruyuki Suzuki
    Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan
    J Am Soc Nephrol 21:2090-8. 2010
    ..Here, we investigated whether minocycline, a selective and potent inhibitor of microglial activation, could protect against ODS in rats...
  62. ncbi CD200 receptors are differentially expressed and modulated by minocycline in the brain during Trypanosoma brucei infection
    Willias Masocha
    Department of Applied Therapeutics, Faculty of Pharmacy, Kuwait University, Kuwait
    J Neuroimmunol 226:59-65. 2010
    ..b>Minocycline treatment inhibited the infection-induced elevation of MAC-1 and CD200RLa transcripts, but had no significant ..
  63. ncbi The effects of tetracycline, minocycline, doxycycline and ofloxacin on Prevotella intermedia biofilm
    N Takahashi
    Oral Health Science Centre, Tokyo Dental College, Masago, Chiba, Japan
    Oral Microbiol Immunol 21:366-71. 2006
    ..The purpose of this study was to examine the effects of four antibiotics, tetracycline (TET), minocycline (MINO), doxycycline (DOXY) and ofloxacin (OFLX) on P...
  64. ncbi Minocycline treatment prevents cavitation in rats after a cortical devascularizing lesion
    Rui Hua
    Department of Physiology, University of Saskatchewan, 107 Wiggins Road, Saskatoon, Canada SK S7N 5E5
    Brain Res 1090:172-81. 2006
    b>Minocycline, a second-generation tetracycline, has been shown to possess neuroprotective effects in animal models of stroke...
  65. ncbi Lymecycline and minocycline in inflammatory acne: a randomized, double-blind intent-to-treat study on clinical and in vivo antibacterial efficacy
    Claudine Pierard-Franchimont
    Department of Dermatopathology, University Medical Center Sart Tilman, Liege, Belgium
    Skin Pharmacol Appl Skin Physiol 15:112-9. 2002
    ..Some antibiotics represent a mainstay in acne treatment. However, studies comparing their efficacies are rare...
  66. ncbi Activity of tigecycline in the treatment of acute Burkholderia pseudomallei infection in a murine model
    Marshall Feterl
    School of Veterinary and Biomedical Sciences, James Cook University, Townsville, Qld 4811, Australia
    Int J Antimicrob Agents 28:460-4. 2006
    ..Tigecycline in combination with ceftazidime was the most effective and conferred the lowest mortality, suggesting the use of this new agent in B. pseudomallei infection...
  67. ncbi Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel
    Joshua S Hawley
    Infectious Disease Service MCHE MDI 7E, Brooke Army Medical Center, 3851 Roger Brooke Dr, Fort Sam Houston, TX 78234, USA
    Antimicrob Agents Chemother 51:376-8. 2007
    ..S. soldiers deployed overseas) to 13 antimicrobial agents were determined by broth microdilution. The most active antimicrobial agents (> or =95% of isolates susceptible) were colistin, polymyxin B, and minocycline.
  68. ncbi Prosthetic vascular conduit in contaminated fields: a new technology to decrease ePTFE infections
    Peter E Fischer
    College of Medicine, Department of Surgery, University of Tennessee Health Science Center, Memphis, Tennessee, USA
    Am Surg 74:524-8; discussion 528-9. 2008
    ..We hypothesized that minocycline and rifampin bound to an ePTFE graft using a unique methacrylate technology would provide for resistance from ..
  69. ncbi Minocycline effectively reduces acid producted by Propionibacterium granulosum
    Shuichi Higaki
    Department of Dermatology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Sugitani, Japan
    J Dermatol 29:20-2. 2002
    We studied the effects of minocycline on Propionibacterium granulosum. P. granulosum lipase activity was detected from acne lesions. Production of propionic and butyric acids by P...
  70. ncbi In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals
    Olivier Denis
    Department of Microbiology, Hopital Erasme, Universite Libre de Bruxelles, 1070 Brussels, Belgium
    Antimicrob Agents Chemother 50:2680-5. 2006
    ....
  71. ncbi Mycobacterium abscessus: an emerging rapid-growing potential pathogen
    Bjorn Petrini
    Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden
    APMIS 114:319-28. 2006
    ..abscessus infection, and if conducted, it should include the removal of all foreign or necrotic material. There is increasing awareness of M. abscessus as an emerging pathogen...
  72. ncbi Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence
    Drosos E Karageorgopoulos
    Alfa Institute of Biomedical Sciences AIBS, Athens, Greece
    J Antimicrob Chemother 62:45-55. 2008
    ..We sought to evaluate the available evidence regarding the microbiological activity and clinical effectiveness of tigecycline for MDR (including the subset of carbapenem-resistant) Acinetobacter spp...
  73. ncbi In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli
    Raymond Cha
    Anti Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan 48201, USA
    Pharmacotherapy 28:295-300. 2008
    ..To evaluate the activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae and Escherichia coli...
  74. ncbi In vitro activities of tigecycline, daptomycin, linezolid and quinupristin/dalfopristin against glycopeptide-resistant Enterococcus faecium
    Jochen Abb
    Int J Antimicrob Agents 29:358-60. 2007
  75. ncbi Prolonged bacterial exposure to minocycline/rifampicin-impregnated vascular catheters does not affect antimicrobial activity of catheters
    Saima Aslam
    Section of Infectious Diseases, Department of Medicine and Center for Prosthesis Infection, Baylor College of Medicine and Michael E DeBakey VA Medical Center, Houston, TX 77030, USA
    J Antimicrob Chemother 60:148-51. 2007
    We assessed the in vitro effect of exposing various bacteria to minocycline/rifampicin-impregnated vascular catheters on the antimicrobial activity of the catheters and the antimicrobial susceptibility of tested organisms.
  76. ncbi In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases
    D J Biedenbach
    University of Iowa College of Medicine, Iowa City, Iowa, USA
    Diagn Microbiol Infect Dis 40:173-7. 2001
    ..The MIC(90)s for GAR-936 were significantly lower than the comparator agents for all species tested with particularly impressive results against S. pneumoniae and enterococci...
  77. ncbi Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control
    Steven D Brown
    The Clinical Microbiology Institute, 9725 SW Commerce Circle, Wilsonville, OR 97070, USA
    J Clin Microbiol 45:2173-9. 2007
    ..03 to 0.12 microg/ml; S. pneumoniae ATCC 49619, 0.015 to 0.12 microg/ml and 23 to 29 mm; Haemophilus influenzae ATCC 49247, 0.06 to 0.5 microg/ml and 23 to 31 mm; and Neisseria gonorrhoeae ATCC 49226, 30 to 40 mm...
  78. ncbi Susceptibility testing of unconventional antibiotics against multiresistant Acinetobacter spp. by agar dilution and Vitek 2
    Thean Yen Tan
    Laboratory Medicine Services, Changi General Hospital, Singapore 529889, Singapore
    Diagn Microbiol Infect Dis 58:357-61. 2007
    ..This study set out to determine the in vitro susceptibility of multiresistant Acinetobacter spp. to colistin, minocycline, and rifampicin using agar dilution, and to compare the accuracy of testing results obtained from an automated ..
  79. ncbi Tigecycline: its potential for treatment of brucellosis
    Murat Dizbay
    Department of Clinical Microbiology and Infectious Diseases, Gazi University School of Medicine, Ankara, Turkey
    Scand J Infect Dis 39:432-4. 2007
    ..The results of this in vitro study suggest tigecycline as a therapeutic alternative for brucellosis. These observations need to be supported with clinical studies...
  80. ncbi Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial
    A C Rodloff
    Institute for Medical Microbiology and Epidemiology of Infectious Diseases, University of Leipzig, Leipzig, Germany
    Clin Microbiol Infect 14:307-14. 2008
    ..The in-vitro activity of tigecycline against both Gram-positive and Gram-negative isolates may make it valuable in the treatment of hospital infections, including those caused by otherwise antimicrobial-resistant organisms...
  81. ncbi In vitro antibacterial activity of tigecycline in comparison with doxycycline, ciprofloxacin and rifampicin against Brucella spp
    Hale Turan
    Int J Antimicrob Agents 30:186-7. 2007
  82. ncbi Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii
    Anton Y Peleg
    Division of Infectious Diseases, Beth Israel Deaconess Medical Center and Harvard Medical School, 110 Francis St, LMOB Suite GB, Boston, MA 02215, USA
    Antimicrob Agents Chemother 51:2065-9. 2007
    ..These results indicate that an efflux-based mechanism plays a role in reduced tigecycline susceptibility in Acinetobacter...
  83. ncbi Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005)
    Do Kyung Lee
    Department of Pharmacy, Sahmyook University, Seoul 139 742, Republic of Korea
    J Biochem Mol Biol 40:881-7. 2007
    ..8 to approximately 1.6 microg/ml. In conclusion, resistances to these new antimicrobial agents were exhibited in most of VRE strains even though these new antibiotics have been rarely used in Korean hospitals...
  84. ncbi Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy
    S Roveta
    Microbiology Section, DISCAT, University of Genoa, Genoa, Italy
    Chemotherapy 54:43-9. 2008
    ..In this study (part of the global TEST program), the in vitro activity of tigecycline, a member of a new class of antimicrobial agents, the glycylcyclines, against clinical isolates collected in Italy was evaluated...
  85. ncbi Delayed combinatorial treatment with flavopiridol and minocycline provides longer term protection for neuronal soma but not dendrites following global ischemia
    Grace O Iyirhiaro
    Ottawa Health Research Institute, Neuroscience Group, University of Ottawa, Ontario, Canada
    J Neurochem 105:703-13. 2008
    ..In the present study, we investigate the ability of delayed flavopiridol in combination with delayed minocycline, another neuroprotectant to provide sustained protection following global ischemia...
  86. ncbi [Pharmacological rationale for choice of antibiotics for intraabdominal infections]
    Teresita Mazzei
    Dipartimento di Farmacologia Preclinica e Clinica, Universita degli Studi di Firenze
    Infez Med 16:31-45. 2008
    ....
  87. ncbi In vitro evaluation of the risk of developing bacterial resistance to antiseptics and antibiotics used in medical devices
    S M Tambe
    Department of Surgery, College of Physicians and Surgeons of Columbia University, 630 West 168th Street, BB 1734, New York, NY 10032, USA
    J Antimicrob Chemother 47:589-98. 2001
    ..There was a 10- to 16-fold increase in the MIC of the combination of minocycline and rifampicin, while no significant increase in the MIC of minocycline alone was seen...
  88. ncbi Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta--lactamase-producing Klebsiella pneumoniae epidemic clone
    Javier Cobo
    Servicio de Enfermedades Infecciosas, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain
    Diagn Microbiol Infect Dis 60:319-22. 2008
    ..Time-kill studies demonstrated that the combination of both compounds was synergistic along the first 12 h, suppressing the regrowth observed after 3 to 6 h when colistin was tested alone...
  89. ncbi Antimicrobial activity of prosthetic heart valve sewing cuffs coated with minocycline and rifampin
    Rabih O Darouiche
    Center for Prostheses Infection, Baylor College of Medicine and Veterans Affairs Medical Center, St Luke s Episcopal Hospital, Houston, Texas 77030, USA
    Antimicrob Agents Chemother 46:543-5. 2002
    Prosthetic heart valve sewing cuffs coated with minocycline and rifampin exhibited in vitro zones of inhibition against all 52 tested clinical isolates responsible for prosthetic valve endocarditis...
  90. ncbi In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii
    Joon Young Song
    Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, Korea University, Seoul, Republic of Korea
    J Antimicrob Chemother 60:317-22. 2007
    ..To determine the in vitro activities and interactions of imipenem, colistin and tigecycline with old antibacterial agents against carbapenem-resistant Acinetobacter baumannii...
  91. ncbi Comparative in vitro efficacies of various catheter lock solutions
    Robert J Sherertz
    Section on Infectious Diseases, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27517, USA
    Antimicrob Agents Chemother 50:1865-8. 2006
    MEDTA (minocycline-edetate calcium disodium), taurolidine (2%)-polyvinylpyrolidine (5%) (T/PVP), and ethanol as potential catheter lock solutions have a unique mechanism of action, broad-spectrum activity, and anticoagulant properties...
  92. ncbi Efficient three-drug cocktail for disease induced by mutant superoxide dismutase
    Jasna Kriz
    Centre for Research in Neurosciences, McGill University, Research Institute of the McGill University Health Centre, , , Canada
    Ann Neurol 53:429-36. 2003
    ..a combination approach consisting of three drugs for distinct targets in the complex pathway to neuronal death: minocycline, an antimicrobial agent that inhibits microglial activation, riluzole, a glutamate antagonist, and nimodipine, ..
  93. ncbi Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial
    Sarvajna Sacchidanand
    Victoria Hospital, Bangalore Medical College, Fort, Bangalore, India
    Int J Infect Dis 9:251-61. 2005
    ..To compare the effect of tigecycline monotherapy, a first-in-class, expanded broad spectrum glycylcycline, with the combination of vancomycin and aztreonam (V + A) in the treatment of complicated skin and skin structure infections (cSSSI)...
  94. ncbi The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam
    E J Ellis-Grosse
    Medical Research Group, Wyeth Research, Collegeville, PA 19426, USA
    Clin Infect Dis 41:S341-53. 2005
    ..Tigecycline monotherapy is as safe and efficacious as the vancomycin-aztreonam combination in treating patients with cSSSI...
  95. ncbi A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline
    Fionnuala McAleese
    Wyeth Research, 401 N Middletown Rd, Pearl River, NY 10965, USA
    Antimicrob Agents Chemother 49:1865-71. 2005
    ..These results suggest that the overexpression of mepA but not tet(M) may contribute to decreased susceptibility of tigecycline in S. aureus...
  96. ncbi Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria
    Richard J Wallace
    Department of Microbiology, University of Texas Health Center, Tyler 75708, USA
    Antimicrob Agents Chemother 46:3164-7. 2002
    ..vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, doxycycline, and minocycline by broth microdilution against 76 isolates belonging to seven species of rapidly growing mycobacteria (RGM) and ..
  97. ncbi In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002
    Samuel K Bouchillon
    Laboratories International for Microbiology Studies, Schaumburg, IL 60179, USA
    Diagn Microbiol Infect Dis 51:291-5. 2005
    ....
  98. ncbi Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms
    Mark W Garrison
    Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, Washington 99210 1495, USA
    Clin Ther 27:12-22. 2005
    ..Tigecycline is an investigational glycylcycline antibiotic that shows promising activity against these resistant gram-positive organisms...
  99. ncbi Rapid development of Acinetobacter baumannii resistance to tigecycline
    Gail E Reid
    Department of Medicine, Section of Infectious Diseases, University of Illinois at Chicago, Chicago, Illinois, USA
    Pharmacotherapy 27:1198-201. 2007
    ..Patients receiving tigecycline for Acinetobacter should be monitored for the development of clinical resistance, and isolates should be monitored for evidence of microbiologic resistance...
  100. ncbi Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination
    Renee Claude Mercier
    College of Pharmacy, University of New Mexico, Albuquerque 87131, USA
    Pharmacotherapy 22:1517-23. 2002
    ..To evaluate the antimicrobial properties of tigecycline, both alone and in combination with other antibiotics, against multidrug-resistant strains of Enterococcus faecium and Staphylococcus aureus...
  101. ncbi Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline
    Kerry L LaPlante
    Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA
    Diagn Microbiol Infect Dis 50:125-30. 2004
    ..68 to 2.74 +/- 0.66. Overall, all the antimicrobials tested (with the exception of vancomycin) exhibited significant in vitro activity against GISS. These compounds may offer therapeutic options for the treatment of GISS...

Research Grants82

  1. Anti-Infective Central Venous Catheter
    MICHAEL VIOLANTE; Fiscal Year: 2002
    ..device that has demonstrated a reduction in infection rates uses a combination of antibiotics (rifampin and minocycline} as the active agents on the catheter surface...
  2. MRS OF NEUROPROTECTION IN AN SIV MODEL OF NEUROAIDS
    Eva Maria Ratai; Fiscal Year: 2007
    ..The long-term goal of this study is to show that minocycline, a well-tolerated, inexpensive antibiotic, can prevent neuronal injury and promote neuronal recovery in an ..
  3. Minocycline Inhibits Immune Reactivation of CNS SIV
    Janice Clements; Fiscal Year: 2009
    ..Using a rigorous SIV/macaque model of HIV AIDS & CNS disease, we have identified the antibiotic minocycline as an excellent candidate to augment HAART...
  4. Minocycline Inhibits Immune Reactivation of CNS SIV
    JANICE ELLEN CLEMENTS; Fiscal Year: 2010
    ..Using a rigorous SIV/macaque model of HIV AIDS &CNS disease, we have identified the antibiotic minocycline as an excellent candidate to augment HAART...
  5. Minocycline Inhibits Immune Reactivation of CNS SIV
    Janice Clements; Fiscal Year: 2007
    ..Using a rigorous SIV/macaque model of HIV AIDS & CNS disease, we have identified the antibiotic minocycline as an excellent candidate to augment HAART...
  6. Krabbe disease: Combined therapies for the central and peripheral nervous systems
    David A Wenger; Fiscal Year: 2010
    ..Initially these drugs will include minocycline and Indomethacin...
  7. The Pathogenesis of Brain Abscess
    Tammy Kielian; Fiscal Year: 2007
    ..The objective of the proposed work is to examine the influences of minocycline and PPAR-gamma agonists on the pathogenesis of brain abscess development...
  8. Minocycline Immune Effects on SIV CNS Disease
    M CHRISTINE contact ZINK; Fiscal Year: 2010
    ..b>Minocycline is a safe and effective antibiotic that has potent anti-inflammatory and neuroprotective activities, inhibits ..
  9. tPA plus MMP inhibition for combination stroke therapy
    ENG LO; Fiscal Year: 2007
    ..focal cerebral ischemia to test the effects of combining rt-PA with the broad spectrum MMP inhibitors BB-94 and minocycline. We will assess the effects of different times of treatment 3-12 h post-ischemia to see whether MMP inhibition ..
  10. tPA plus MMP inhibition for combination stroke therapy
    Eng H Lo; Fiscal Year: 2010
    ..focal cerebral ischemia to test the effects of combining rt-PA with the broad spectrum MMP inhibitors BB-94 and minocycline. We will assess the effects of different times of treatment 3-12 h post-ischemia to see whether MMP inhibition ..
  11. Matrix metalloproteinases as biomarkers of neurodegeneration
    Veronica Shubayev; Fiscal Year: 2007
    ..e. riluzole, dizocilpine, minocycline)...
  12. CNS Mechanisms of MCP-1 Transcription
    Janice Clements; Fiscal Year: 2007
    ..Further, treatment of SIV-infected macaques with minocycline, a potent neuroprotective, anti-inflammatory drug significantly reduced activation of p38, reduced ratios of ..
  13. Mechanisms and modulation of disease progression in ALS
    Robert Friedlander; Fiscal Year: 2005
    ..The regulation of additional caspases will be evaluated. 3) Evaluate a potential therapeutic role for minocycline in ALS. Investigate the mechanisms of minocycline-mediated neuroprotection...
  14. CNS Mechanisms of MCP-1 Transcription
    Sheila Barber; Fiscal Year: 2005
    ..Further, treatment of SIV-infected macaques with minocycline, a potent neuroprotective, anti-inflammatory drug significantly reduced activation of p38, reduced ratios of ..
  15. Modified Late Infarct Reperfusion to Prevent Post MI CHF
    Robert Gorman; Fiscal Year: 2006
    ..Adenosine, abciximab and minocycline have been selected to modify the infarct reperfusate because they have been demonstrated in clinical and/or ..
  16. Photoconductive stimulation of synapses and HIV neurotoxins
    Harris Gelbard; Fiscal Year: 2007
    ..exposure), whether microglial responses affect synaptic transmission, and whether the microglial deactivator minocycline can prevent this type of injury...
  17. HEMODYNAMICS OF CEREBRAL ARTERIOVENOUS MALFORMATIONS
    William Young; Fiscal Year: 2007
    ..then demonstrate that this vascular dysplasia can be attenuated by inhibition of MMP-9 activity using either minocycline or the MMP inhibitor GM6001 These aims will establish potential mechanistic pathways of AVM pathogenesis to ..
  18. Repair of Bladder Function after Cauda Equina Injury
    Leif A Havton; Fiscal Year: 2010
    ..after a lumbosacral ventral root avulsion (VRA) injury;2) to determine potential neuroprotective effects of minocycline and complement inhibition;3) determine whether minocycline and/or complement inhibition may augment functional ..
  19. Repair of Bladder Function after Cauda Equina Injury
    LEIF HAVTON; Fiscal Year: 2009
    ..after a lumbosacral ventral root avulsion (VRA) injury; 2) to determine potential neuroprotective effects of minocycline and complement inhibition; 3) determine whether minocycline and/or complement inhibition may augment functional ..
  20. Repair of Bladder Function after Cauda Equina Injury
    LEIF HAVTON; Fiscal Year: 2009
    ..after a lumbosacral ventral root avulsion (VRA) injury; 2) to determine potential neuroprotective effects of minocycline and complement inhibition; 3) determine whether minocycline and/or complement inhibition may augment functional ..
  21. Repair of Bladder Function after Cauda Equina Injury
    Leif A Havton; Fiscal Year: 2010
    ..after a lumbosacral ventral root avulsion (VRA) injury;2) to determine potential neuroprotective effects of minocycline and complement inhibition;3) determine whether minocycline and/or complement inhibition may augment functional ..
  22. Microglia: Role in Motoneuron Degeneration/Regeneration
    Wolfgang Streit; Fiscal Year: 2005
    ..3) To determine the effect of minocycline treatment on axotomy-induced microglial activation in wildtype Sprague Dawley rats...
  23. PAIN EVOKED RELEASE OF AMINO ACIDS AND PROSTANOIDS
    Tony Yaksh; Fiscal Year: 2007
    ..3) Given the role of microglia, spinal blockade of activation using agents such as minocycline or pentoxifylline will block: P38 activation, evoked release of spinal PG, COX2 upregulation and hyperalgesia...
  24. Inflammatory mechanisms associated with HIV-1 dementia
    Sanjay Maggirwar; Fiscal Year: 2007
    ..associated with CD40 engagement, including analyses of the anti- inflammatory effects of NF-KB inhibitors, minocycline and glitazones...
  25. MOLECULAR PHYSIOLOGY OF RESPIRATORY MUSCLES
    Jeffrey Miller; Fiscal Year: 2007
    ..For Specific Aim 1, we will use the Lama2-nu\\ mouse model to test known anti-apoptosis drugs, such as minocycline and caspase inhibitors, as potential pharmacological therapies for CMD1 A...
  26. Phase III Trial of Minocycline in ALS-II Data Center
    Robert Miller; Fiscal Year: 2006
    ..is designed to provide data management and statistical support for the companion application Phase III Trial of Minocycline in ALS: I-Clinical Center (P.I...
  27. Phase III Trial of Minocycline in ALS-II Data Center
    Robert Miller; Fiscal Year: 2007
    ..is designed to provide data management and statistical support for the companion application Phase Ill Trial of Minocycline in ALS: I--Clinical Center (P.I...
  28. Neuroinflammation in Cholesterol-Induced AD Pathogenesis
    Narayan Bhat; Fiscal Year: 2009
    ..of a synthetic LXR ligand (T0901317) with both cholesterol lowering and anti-inflammatory properties, and minocycline, a tetracycline derivative known to suppress microglial activa- tion, by examining neuropathological (i.e...
  29. Neuroinflammation in Cholesterol-Induced AD Pathogenesis
    Narayan Bhat; Fiscal Year: 2007
    ..of a synthetic LXR ligand (T0901317) with both cholesterol lowering and anti-inflammatory properties, and minocycline, a tetracycline derivative known to suppress microglial activation, by examining neuropathological (i.e...